Ovarian Cancer Clinical Trial
Dietary Magnesium in Preventing Low Blood Magnesium Levels in Patients With Ovarian Cancer Receiving Carboplatin Chemotherapy
Summary
This trial studies how well a diet high in magnesium works in preventing low blood magnesium levels (hypomagnesemia) in patients with ovarian cancer receiving carboplatin chemotherapy. Hypomagnesemia is a common side effect of carboplatin-containing chemotherapy. A magnesium rich diet may increase the levels of magnesium in the blood and help prevent hypomagnesemia resulting from carboplatin chemotherapy.
Full Description
PRIMARY OBJECTIVE:
I. Evaluate intervention feasibility.
SECONDARY OBJECTIVE:
I. Evaluate occurrence of hypomagnesemia and the need for a pharmacy regimen including oral and intravenous magnesium dosage.
EXPLORATORY OBJECTIVE:
I. Explore changes in other electrolytes, weight, and occurrence of chemotherapy delay or discontinuation and hospitalization which can be related to dietary intervention and program completion.
OUTLINE:
Patients receive a dietary magnesium intervention consisting of a food reference list and phone calls or video interviews from a registered dietitian, integrative medicine physician, or a mid-level provider over 10-20 minutes once a week for up to the 6th cycle of chemotherapy (average 15 weeks).
Eligibility Criteria
Inclusion Criteria:
Patients with previously untreated ovarian cancer.
Receiving carboplatin-containing chemotherapy of at least 6 consecutive cycles.
Able to tolerate an oral diet.
Exclusion Criteria:
Prior platinum-based chemotherapy.
Serum creatinine level > 1.4 mg/dL prior to treatment.
Artificial nutrition (e.g. Ensure or Boost) accounts for > 50% of total calorie intake.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Houston Texas, 77030, United States
How clear is this clinincal trial information?